After a median follow up of 14.6 months in the placebo group, and 14.9 months in the pazopanib group, the median progression-free survival was 4.6 months for pazopanib vs 1.6 months in the placebo group (HR=0.31; 95% CI 0.24-0.40; p<0.0001). Overall survival did not reach significance for pazopanib 12.5 months vs 10.7 months for placebo (HR 0.86; 95% CI 0.67-1.11; p=0.25).r
Kaplan Meier curves for Median PFS and OS:r
© Lancet 2012
Best overall response (determined by external review) was 0% for placebo and 6% in the pazopanib for partial response, 38% for placebo and 67% for pazopanib for stable disease, and 57% for placebo and 23% for pazopanib for disease progression.
Following multivariate analysis, good performance status and a low or intermediate tumour grade were demonstrated to be favourable prognostic factors in patients treated with pazopanib. The interaction between histologic subtype and progression-free survival rates was not found to be significant.
© Lancet 2012
Quality of life data, collected at baseline, and week 4,8 and 12 has been reported separately.r At no time point was there any statistically or clinically significant difference between the two treatment arms. As QoL data collection as ceased at 12 weeks, no conclusions can be drawn about the effect of pazopanib for the entire progression-free period.